Comments
Sun Pharmaceutical Industries Ltd has got final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Depo-Testosterone Injection, Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml.
The generic Testosterone Cypionate Injection USP, 100 mg/ml and 200mg/ml was “therapeutically equivalent to Depo-Testosterone Injection of Pfizer Inc’’ , the company said in its filing to the stock exchanges.
The drug was indicated for replacement therapy in males for conditions associated with symptoms of deficiency or absence of endogenous testosterone and the product generated annual revenue of nearly $130 million in the US, it said.
Shares of Sun Pharma closed at Rs 1,018.80, down by Rs 1.30, on the BSE today. After touching a 52-week high of Rs 1,085.40 on May 30, the scrip has ceded some of its gains.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.